Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 1.00 |
| ▸ | ADORA2A | P29274 | 3/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 2/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | THPO | P40225 | 1/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 5/20 | 0.98 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.98 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.98 |
| ▸ | MEN1 | O00255 | 2/20 | 0.98 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.98 |
| ▸ | GAA | P10253 | 1/20 | 0.98 |
| ▸ | HTT | P42858 | 1/20 | 0.98 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.98 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.98 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.98 |
| ▸ | TP53 | P04637 | 1/20 | 0.98 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.98 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12119008 | 1.00 | TSHR (1.00) | TSHRADORA2APMP22SMN1; SMN2TDP1 | |
| SCHEMBL145856 | 1.00 | TSHR (1.00) | TSHRADORA2APMP22SMN1; SMN2TDP1 | |
| SCHEMBL472771 | 1.00 | TSHR (1.00) | TSHRADORA2APMP22SMN1; SMN2TDP1 | |
| SCHEMBL27097764 | 1.00 | TSHR (1.00) | TSHRADORA2APMP22SMN1; SMN2TDP1 | |
| SCHEMBL145857 | 1.00 | TSHR (1.00) | TSHRADORA2APMP22SMN1; SMN2TDP1 | |
| SCHEMBL472589 | 1.00 | TSHR (1.00) | TSHRADORA2APMP22SMN1; SMN2TDP1 | |
| SCHEMBL16081270 | 1.00 | TSHR (1.00) | TSHRADORA2APMP22SMN1; SMN2TDP1 | |
| SCHEMBL472588 | 1.00 | TSHR (1.00) | TSHRADORA2APMP22SMN1; SMN2TDP1 | |
| N6-Cyclopentyladenosine SCHEMBL18908968 | 0.99 | ADORA3 (1.00) | TSHRADORA2APMP22SMN1; SMN2TDP1 | |
| N6-Cyclopentyladenosine SCHEMBL120481 | 0.99 | ADORA3 (1.00) | TSHRADORA2APMP22SMN1; SMN2TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11911408-B2 | Synergistic formulations of adenosine receptor modulating agents and anticholinergics | UNIVERSITY OF ALASKA FAIRBANKS (US) | 2024-02-27 | — | — | US | disclosed |
| US-20150238513-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF ISCHEMIC INJURY TO TISSUE USING THERAPEUTIC HYPOTHERMIA | UNIVERSITY OF ALASKA FAIRBANKS (US) | 2015-08-27 | — | — | US | disclosed |
| US-20150238513-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF ISCHEMIC INJURY TO TISSUE USING THERAPEUTIC HYPOTHERMIA | UNIVERSITY OF ALASKA FAIRBANKS (US) | 2015-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11911408-B2 | Synergistic formulations of adenosine receptor modulating agents and anticholinergics | ADORA1, ADORA3, ADORA2A | TSHR 235/4885ADORA2A 3/4885PMP22 4619/4885 |
| US-20150238513-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF ISCHEMIC INJURY TO TISSUE USING THERAPEUTIC HYPOTHERMIA | TNNI3, TNNC1, TNNT2 | TSHR 3156/4885ADORA2A 912/4885PMP22 518/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.